½ÃÀ庸°í¼­
»óǰÄÚµå
1532513

¼¼°èÀÇ ¶óÅØ½º ÀÀÁý Å×½ºÆ® ŰƮ ½ÃÀå : Å×½ºÆ® À¯Çüº°, °¨¿°Áõ À¯Çüº°, »ùÇà À¯Çüº°, ÃÖÁ¾ ¿ëµµº° - ¿¹Ãø(2024-2032³â)

Latex Agglutination Test Kits Market, By Test Type (Antibody Detection, Antigen Testing), Infection Type (Streptococcus, Staphylococcus, Escherichia, Salmonella), Sample Type (Blood, Urine, Cerebrospinal Fluid), End-use - Global Forecast 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 231 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¶óÅØ½º ÀÀÁý Å×½ºÆ® ŰƮ ½ÃÀå ±Ô¸ð´Â °¨¿°ÁõÀÇ ¸¸¿¬ Áõ°¡¿¡ ÈûÀÔ¾î 2024³âºÎÅÍ 2032³â±îÁö 6.5% ÀÌ»óÀÇ CAGRÀ» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. 2023³â WHOÀÇ º¸°í¿¡ µû¸£¸é °áÇÙ µîÀÇ °¨¿°ÁõÀÇ ¼¼°è Áõ·Ê´Â 2019³âºÎÅÍ 2023³â±îÁö 10% Áõ°¡ÇßÀ¸¸ç, 2023³â ½Å±Ô Áõ·Ê´Â ¾à 1,060¸¸¸í¿¡ ´ÞÇß½À´Ï´Ù.

Àü¿°º´ÀÇ ÀÌȯÀ²ÀÌ ¼¼°èÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó, ½Å¼ÓÇÏ°Ô °ËÃâÇÏ°í °ü¸®ÇÏ´Â È¿°úÀûÀÌ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸ÀÇ Çʿ伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù. ¶óÅØ½º ÀÀÁý Å×½ºÆ®´Â ½Å¼ÓÇϰí Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇÒ ¼ö Àֱ⠶§¹®¿¡ °¨¿° ¹ß»ý°úÀÇ ½Î¿ò¿¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü Á¤È®µµ¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡´Â Áø´Ü ±â¼úÀÇ Çõ½Å°ú Á¦Ç° äÅà Ȯ´ë·Î À̾îÁ® ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

¶óÅØ½º ÀÀÁý Å×½ºÆ® ŰƮ ½ÃÀåÀº Å×½ºÆ® À¯Çüº°, °¨¿° À¯Çüº°, »ùÇà À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

Ç×ü °ËÃ⠺ι®Àº ºü¸£°í Á¤È®ÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ °á°ú¸¦ Á¦°øÇÒ ¼ö Àֱ⠶§¹®¿¡ 2032³â±îÁö ÇöÀúÇÑ CAGRÀ» º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Å×½ºÆ®´Â ƯÁ¤ Ç×ü¸¦ È®ÀÎÇϰí Á¤·®ÇÏ´Â µ¥ Áß¿äÇÏ¸ç ´Ù¾çÇÑ Áúº´ÀÇ Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÇ·á Á¦°ø¾÷ü°¡ ¸ÂÃãÇü ÀÇ·á ¹× Á¶±â Áúȯ ¹ß°ß¿¡ Á¡Á¡ ´õ ÁßÁ¡À» µÎ°Ô µÊ¿¡ µû¶ó È¿À²ÀûÀÎ Ç×ü °ËÃâ µµ±¸ÀÇ Çʿ伺ÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ¿¹¹æÀǷᳪ ÀÏ»óÀûÀÎ ½ºÅ©¸®´×ÀÌ Áß½ÃµÇ°Ô µÈ °Íµµ, Ç×ü °ËÃâ¿ë ¶óÅØ½º ÀÀÁý Å×½ºÆ® ŰƮ¿¡ ´ëÇÑ °ü½ÉÀÇ °íÁ¶¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Æ÷µµ»ó±¸±Õ ºÐÀýÀº ÀÌ ¹ÚÅ׸®¾ÆÀÇ Ç×»ýÁ¦ ³»¼º ±ÕÁÖ¿¡ ´ëÇÑ ¿ì·Á°¡ ³ô¾ÆÁü¿¡ µû¶ó 2032³â±îÁö »ó´çÇÑ ½ÃÀå Á¡À¯À²À» ȹµæÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ½ºÅ¸ÇÊ·ÎÄÚÄ¿½º ¾Æ¿ì·¹¿ì½º, ƯÈ÷ ¸ÞƼ½Ç¸° ³»¼º ½ºÅ¸ÇÊ·ÎÄÚÄ¿½º ¾Æ¿ì·¹¿ì½º(MRSA)´Â Ä¡·á¿¡ Å« ¾î·Á¿òÀ» ¾ß±âÇϱ⠶§¹®¿¡ È¿°úÀûÀÎ °ü¸®¸¦ À§Çؼ­´Â Á¤È®ÇÏ°í ½Å¼ÓÇÑ °ËÃâÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÀÇ·á ÇöÀå¿¡¼­´Â Àû½Ã¿¡ °³ÀÔ°ú ÀûÀýÇÑ Ä¡·á¸¦ º¸ÀåÇϱâ À§ÇØ ÀÌ·¯ÇÑ °¨¿°À» ½Å¼ÓÇÏ°Ô ½Äº°ÇÏ´Â µµ±¸°¡ ¿ì¼±ÇÕ´Ï´Ù. ÀÌ ¶§¹®¿¡ Ȳ»ö Æ÷µµ»ó ±¸±Õ °¨¿°À» °ËÃâÇϱâ À§ÇØ Á¶Á¤µÈ Ư¼ö Å×½ºÆ® ŰƮ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ¶óÅØ½º ÀÀÁý Å×½ºÆ® ŰƮ ½ÃÀåÀº ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í Áø´Ü ±â¼úÀÇ Áøº¸·Î ¿¹Ãø ±â°£ µ¿¾È ÇöÀúÇÑ CAGRÀ» ±â·ÏÇÒ Àü¸ÁÀÔ´Ï´Ù. Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¸ÂÃãÇü ÀÇ·á°¡ Á߽õǾî Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´Ü µµ±¸ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¨¿° ´ëÃ¥°ú ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡µµ Á¦Ç° ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ºÐ¾ß¿¡¼­´Â Çõ½ÅÀûÀ̰í È¿À²ÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀÇ µµÀÔ¿¡ ÁßÁ¡À» µÎ°í Àֱ⠶§¹®¿¡ ¿¬±¸ Àڱݰú ±â¼ú Áøº¸°¡ ÃËÁøµÇ¾î ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè ¹× °úÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±â¼úÀû Àü¸Á
  • ±ÔÁ¦ »óȲ
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­¹®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« Àü¸Á ¸ÅÆ®¸¯½º

Á¦5Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : °Ë»ç À¯Çüº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • Ç×ü °ËÃâ
  • Ç׿ø °Ë»ç

Á¦6Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : °¨¿°Áõ À¯Çüº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ¿ë·Ã±Õ
  • Ȳ»ö Æ÷µµ»ó ±¸±Õ
  • ´ëÀå±Õ
  • »ì¸ð³Ú¶ó±Õ
  • ±âŸ °¨¿°Áõ

Á¦7Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : »ùÇà À¯Çüº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • Ç÷¾×
  • ¼Òº¯
  • ³úô¼ö¾×
  • ±âŸ »ùÇà À¯Çü

Á¦8Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¿ëµµº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • Áø´Ü ½ÇÇè½Ç
  • Çмú±â°ü ¹× ¿¬±¸±â°ü

Á¦9Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Áö¿ªº°(2021-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Atlas Medical GmbH
  • Arlington Scientific, Inc
  • Bio-Rad Laboratories, Inc.
  • bioMerieuxSA
  • Biotium
  • Creative Diagnostics
  • Cardinal Health, Inc.
  • Eurofins Scientific Group
  • Hardy plc
  • HiMedia Laboratories
  • Liofilchem Srl
  • Novacyt Group
  • PerkinElmer, Inc.
  • Pro Lab Diagnostics
  • Thermo Fisher Scientific Inc.
AJY 24.08.22

Global Latex Agglutination Test Kits Market will experience over 6.5% CAGR from 2024 to 2032, thrusted by the growing prevalence of infectious diseases. According to the WHO reports in 2023, global cases of infectious diseases such as tuberculosis TB increased by 10% from 2019 to 2023, reaching approximately 10.6 million new cases in 2023.

As the incidence rate of infectious ailment rises globally, there is an increasing need for effective and reliable diagnostic tools to detect and manage them promptly. The ability of latex agglutination tests to deliver rapid and accurate results makes them crucial in the fight against infectious outbreaks. This heightened demand for diagnostic accuracy leads to innovation in diagnostic technology and greater product adoption, accelerating market growth.

The latex agglutination test kits market is categorized based on test type, infection type, sample type, end-use, and region.

The antibody detection segment will exhibit a noticeable CAGR through 2032, catapulted by its ability to offer quick, precise, and cost-effective results. These tests are important for identifying and quantifying specific antibodies, which is crucial in diagnosing and monitoring various diseases. As healthcare providers increasingly focus on personalized medicine and early disease detection, the need for efficient antibody detection tools has surged. Additionally, the growing emphasis on preventive healthcare and routine screening contributes to the heightened interest in latex agglutination test kits for antibody detection.

The staphylococcus segment will grab a substantial market share by 2032, owing to the growing concern over antibiotic-resistant strains of this bacterium. Staphylococcus aureus, particularly methicillin-resistant Staphylococcus aureus MRSA, poses significant treatment challenges, making accurate and rapid detection essential for effective management. Healthcare settings are prioritizing tools that swiftly identify these infections to ensure timely intervention and appropriate treatment. This will drive the demand for specialized test kits tailored to detect Staphylococcus aureus infections.

North America latex agglutination test kits market will register a prominent CAGR during the forecast period, because of increased investment in healthcare infrastructure and advancements in diagnostic technology. The strong emphasis on early disease detection and personalized medicine spurs the need for accurate and rapid diagnostic tools. Additionally, heightened awareness of infection control and preventive healthcare measures contributes to the rising product demand. The focus in healthcare sector on adopting innovative and efficient diagnostic solutions is favoring research funding and technological advancements, thereby propelling the market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of infectious and autoimmune diseases
      • 3.2.1.2 Increasing demand for point-of-care testing (POCT)
      • 3.2.1.3 Technological innovations
      • 3.2.1.4 Increasing awareness and screening programs
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Antibody detection
  • 5.3 Antigen testing

Chapter 6 Market Estimates and Forecast, By Infection Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Streptococcus
  • 6.3 Staphylococcus Aureus
  • 6.4 Escherichia Coli
  • 6.5 Salmonella Spp.
  • 6.6 Other infection types

Chapter 7 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Blood
  • 7.3 Urine
  • 7.4 Cerebrospinal fluid
  • 7.5 Other sample types

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Diagnostic laboratories
  • 8.4 Academic and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Atlas Medical GmbH
  • 10.2 Arlington Scientific, Inc
  • 10.3 Bio-Rad Laboratories, Inc.
  • 10.4 bioMerieuxSA
  • 10.5 Biotium
  • 10.6 Creative Diagnostics
  • 10.7 Cardinal Health, Inc.
  • 10.8 Eurofins Scientific Group
  • 10.9 Hardy plc
  • 10.10 HiMedia Laboratories
  • 10.11 Liofilchem S.r.l.
  • 10.12 Novacyt Group
  • 10.13 PerkinElmer, Inc.
  • 10.14 Pro Lab Diagnostics
  • 10.15 Thermo Fisher Scientific Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦